Q1 EPS Estimate for Bicara Therapeutics Lowered by Analyst

Bicara Therapeutics Inc. (NASDAQ:BCAX) – Equities research analysts at Wedbush cut their Q1 2025 EPS estimates for Bicara Therapeutics in a note issued to investors on Thursday, March 27th. Wedbush analyst D. Nierengarten now expects that the company will post earnings of ($0.40) per share for the quarter, down from their prior estimate of ($0.33). Wedbush has a “Outperform” rating and a $31.00 price target on the stock. The consensus estimate for Bicara Therapeutics’ current full-year earnings is ($2.59) per share. Wedbush also issued estimates for Bicara Therapeutics’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.67) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.46) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($1.87) EPS and FY2027 earnings at ($2.10) EPS.

A number of other analysts have also issued reports on BCAX. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $13.01 target price on shares of Bicara Therapeutics in a research report on Thursday, March 13th. HC Wainwright lifted their price objective on Bicara Therapeutics from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $36.50.

Bicara Therapeutics Price Performance

NASDAQ BCAX opened at $13.40 on Monday. Bicara Therapeutics has a fifty-two week low of $11.10 and a fifty-two week high of $28.09. The business has a 50 day moving average of $13.04.

Bicara Therapeutics (NASDAQ:BCAX) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.08).

Institutional Investors Weigh In On Bicara Therapeutics

Several institutional investors have recently made changes to their positions in the company. California State Teachers Retirement System acquired a new position in Bicara Therapeutics during the fourth quarter worth $25,000. Spire Wealth Management bought a new stake in shares of Bicara Therapeutics during the 4th quarter worth about $31,000. BNP Paribas Financial Markets acquired a new position in shares of Bicara Therapeutics during the 4th quarter valued at about $32,000. Legal & General Group Plc bought a new position in shares of Bicara Therapeutics in the 4th quarter valued at approximately $33,000. Finally, Summit Investment Advisors Inc. acquired a new stake in Bicara Therapeutics in the 4th quarter worth approximately $35,000.

Bicara Therapeutics Company Profile

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.